
Badir Delf Loveymi, Mitra Jelvehgari, Parvin Zakeri-Milani and Hadi Valizadeh

Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

A Box-Behnken design with three replicates was used for preparation and evaluation of Eudragit vancomycin (VCM) nanoparticles prepared by double emulsion. The purpose of this work was to optimize VCM nanoparticles to improve the physicochemical properties. Nanoparticles were formed by using W1/O/W2 double-emulsion solvent evaporation method using Eudragit RS as a retardant material. Full factorial design was employed to study the effect of independent variables, RPM (X1), amount of emulsifier (X2), stirring rate (X3), volume of organic phase (X4) and volume of aqueous phase (X5), on the dependent variables as production yield, encapsulation efficiency and particle size. The optimum condition for VCM nanoparticles preparation was 1:2 drug to polymer ratio, 0.2 (%w/w) amount of emulsifier, 25 mL (volume of organic phase), 25 mL (volume of aqueous phase), 3 min (time of stirring) and 26000 RPM. RPM and emulsifier concentrations were the effective factors on the drug loading (R2 = 90.82). The highest entrapment efficiency was obtained when the ratio of drug to polymer was 1:3. Zeta (ζ) potential of the nanoparticles was fairly positive in molecular level. In vitro release study showed two phases: an initial burst for 0.5 h followed by a very slow release pattern during a period of 24 h. The release of VCM was influenced by the drug to polymer ratio and particle size and was found to be diffusion controlled. The best-fit release kinetic was achieved with Peppas model. In conclusion, the VCM nanoparticle preparations showed optimize formulation, which can be useful for oral administrations.

Keywords: Vancomycin; Nanoparticles; Eudragit RS100; Optimization; Response surface methodology.

Introduction

Vancomycin (VCM) is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis at an earlier stage than the beta-lactam antibiotic. Since the oral absorption of VCM is minimal, it is usually given IV (1). VCM is used for the treatment of infections caused by methicillin-resistant staphylococci. It has a high molecular weight and is water-soluble and poorly absorbable from the gastrointestinal tract (2). The oral absorption of highly polar and macromolecular drugs is frequently limited by poor intestinal wall permeability. Some physicochemical properties that have been associated with poor membrane permeability are low octanol/aqueous partitioning, the presence of strongly charged functional groups, high molecular weight, a substantial number of
hydrogen-bonding functional groups and high polar surface area (3, 4).

Many therapeutic compounds such as antibiotics and peptide and protein drugs require the use of some kind of absorption enhancer to obtain reasonable plasma concentrations. By loading antibiotics into the nanoparticles, one can expect improved delivery to infected cells. Nanoparticles are the carriers developed for these logistic targeting strategies and are colloidal in nature, biodegradable and similar in behavior to intracellular pathogens. These colloidal carriers, when administered intravenously, are rapidly taken up by the cells of the mononuclear phagocytic system, the very cells which may constitute a sanctuary for intracellular bacteria (5, 6). Therefore, the entrapment of antibiotics within nanoparticles has been proposed for the treatment of intracellular infections (5). The encapsulation of VCM in liposomes and microspheres has been described in previous works (1-3). It has been proposed that VCM-PLGA-loaded microspheres may show a better bioavailability than the free drug (3). Eudragit RS 100 is a polymer commonly used for the preparation of controlled-release oral pharmaceutical dosage forms. Eudragit RS100 contains different amounts of quaternary ammonium groups ranging from 4.5-6.8% and is a neutral copolymer of poly (chlorotrimethylammonioethyl methacrylate). As Eudragit RS 100 is insoluble at physiological pH values, it has been used as a good polymer for the preparation of pH-independent sustained-release formulations of drugs (7). Various non-biodegradable polymers with good biocompatibility such as Eudragit and ethyl cellulose have been used in the preparation of microspheres. Polymethylmethacrylate microspheres were extensively used as bone cement materials in antibiotic releasing agents for bone infection and bone tumors (7). Double-emulsion solvent extraction/evaporation technique is the most commonly used method to encapsulate hydrophilic drugs, especially protein and glycoprotein drugs, into polymeric microspheres (8). Indeed, the presence of a polymeric wall provides a protection from the gastrointestinal environment and may favor a prolonged contact with the epithelium that may be sufficient to increase the bioavailability of certain drugs.

Response surface methodology is a useful tool in the development and optimization of controlled release nanoparticles (9). Different steps involved in response surface methodology include experimental design, regression analysis, constraint optimization and validation.

Response surface methodology (RSM) is a widely practiced approach in the development and optimization of drug delivery devices. Based on the principle of design of experiments (DoEs), the methodology encompasses the use of various types of experimental designs, generation of polynomial equations, and mapping of the response over the experimental domain to determine the optimum formulation(s) (10). The technique requires minimum experimentation and time, thus proving to be far more effective and cost-effective than the conventional methods of formulating dosage forms.

In the present investigation, the effect of factors (rpm, volume of organic phase, aqueous phase, time of stirring and concentration emulsifier) that can influence the drug loading, loading efficiency, particle size and production yield of VCM nanoparticles from Eudragit RS was investigated.

**Experimental**

Vancomycin hydrochloride was obtained from Jaberabne Hyán Pharmaceutical Company, Iran. Edragit RS 100 was obtained from RÖhm Pharma GMBh (RÖhm Pharma GMBh, Weiterstadt, Germany). Poly vinyl alcohol (PVA) with molecular weight of MW 95000 was obtained from Acros Organics (Acros Organics, Geel, Belgium) and dichloromethane, methanol, glacial acetic acid, triethanolamine, hydrochloric acid, potassium chloride, sodium chloride, sodium hydrogen phosphate (dibasic), and potassium dihydrogen phosphate were obtained from Merck (Merck, Darmstadt, Germany). Silastic membrane (#10,000 Da) was provided by Biogene (Mashhad, Iran). All other materials used were of analytical or HPLC grade.

**Experimental design**

The experimental design was a modified Box-Behnken design for five variables. This
design was suitable for exploring quadratic response surfaces and constructing second-order polynomial models. Four independent formulation variables analyzed during the study including the amounts of emulsifier ($X_1$), volume of organic solvent ($X_2$), and the amount of dispersing medium ($X_3$), time of stirring ($X_4$) and rate of stirring ($X_5$). The investigated dependent variables were the drug content (DC, $Y_1$), loading efficiency (LE, $Y_2$), particle size (PS, $Y_3$), and production yield (PY, $Y_4$). The complete design consisted of 27 experimental points, which are included three replications. The 81 experiments were carried out in random order. Data were analyzed to fit the polynomial equation to $Y$ (9).

Preparation of nanoparticles
VCM-loaded Eudragit RS100 nanoparticles were prepared by W$_1$/O/W$_2$ solvent evaporation method using different ratios of drug to polymer (1:1, 1: 2 and 1: 3). Briefly, 5 mL of aqueous internal phase (containing 100 mg VCM) was emulsified for 15 sec in 20 mL of methylene chloride (containing 100, 200 and 300 mg Eudragit RS100) using homogenizer (22000 rpm). This primary emulsion was poured into 25 mL of a 0.2% PVA aqueous solution while stirring using a homogenizer for 3 min, immersed in an ice water bath, to create the water in oil-in-water emulsion. Three to four mL of NP suspension was obtained after the solvent evaporation under reduced pressure (Evaporator, Heidolph, USA). Nanoparticles were separated from the bulk suspension by centrifugation (Hettich universal 320R, USA) at 22,000 g for 20 min. The supernatant was kept for drug assay as described later and the sediment nanoparticles were collected and washed with three portions of 30 mL water and were redispersed in 5 mL of purified water before freeze-drying. Blank nanoparticles (without drug) were prepared under the same conditions (11, 12).

Micromeritic properties
A laser light scattering particle size analyzer (SALD-2101, Shimadzu, Japan) was used to determine the particle size of the drug, polymer and nanoparticulate formulations. Samples were suspended in distilled water (nanoparticles and polymer) or acetone (drug) in a 1 cm cuvette and stirred continuously during the particle size analysis.

Zeta potential measurement
Zeta ($\zeta$) potential measurements of diluted samples were made with a ZetaSizer (Malvern Instruments Ltd., Malvern, UK). Zeta potential values obtained from ZetaSizer were average values from twenty measurements made on the same sample. Initial measurements on several samples of the same kind showed that this number is sufficient to give a representative average value. VCM nanoparticles were diluted with deionized water before the measurement.

Loading efficiency and production yield (%) determination
The drug concentration in polymeric particles was determined spectrophotometrically (UV-160, Shimadzu, Japan) at 280.2 nm by measuring the amount of non-entrapped VCM in the external aqueous solution (indirect method) before freeze-drying. In the case of nanoparticles, the external aqueous solution was obtained after the centrifugation of colloidal suspension for 20 min at 22,000 g.

The loading efficiency (%) was calculated

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Drug: polymer ratios</th>
<th>Production yield (% ± SD)</th>
<th>Theoretical drug Content (%)</th>
<th>Mean drug Entrapped (% ± SD)</th>
<th>Drug loading efficiency (% ± SD)</th>
<th>Mean particle Size (nm±SD)</th>
<th>Zeta Potential (mV±SD)</th>
<th>Polydispersity Index (PDI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$F_1$</td>
<td>1:1</td>
<td>96.38 ± 1.65</td>
<td>50</td>
<td>30.25 ± 1.04</td>
<td>63 ± 2.19</td>
<td>362 ± 29.26</td>
<td>18.1±8.82</td>
<td>0.0099</td>
</tr>
<tr>
<td>$F_2$</td>
<td>1:2</td>
<td>97.84 ± 1.54</td>
<td>33.33</td>
<td>29.79 ± 1.12</td>
<td>89.37 ± 2.36</td>
<td>430 ± 31.94</td>
<td>25.7±9.72</td>
<td>0.0055</td>
</tr>
<tr>
<td>$F_3$</td>
<td>1:3</td>
<td>98.35 ± 1.87</td>
<td>25</td>
<td>23.69 ± 1.02</td>
<td>94.76 ± 1.95</td>
<td>499 ± 110</td>
<td>24.1±7.17</td>
<td>0.0034</td>
</tr>
</tbody>
</table>

Table 1. Effect of drug: polymer ratio on drug loading efficiency, production yield, particle size zeta potential and polydispersity index of vancomycin nanoparticles.
Loading efficiency(%) = \( \frac{\text{actual drug content in nanoparticles}}{\text{theoretical drug content}} \times 100 \)

The production yield of the nanoparticles was determined by accurately calculating the initial weight of the raw materials and the last weight of the polymeric particles obtained. All of the experiments were performed in triplicate (Table 1).

**In-vitro release study**

VCM dissolution patterns from freeze-dried nanoparticles were obtained under sinking conditions. Dissolution studies were carried out using a dialysis bag rotating method. A set amount of nanoparticles (20 mg of drug) was added to 200 mL dissolution medium (phosphate buffered saline, pH = 7.4), preheated and maintained at 37 ± 1°C in a water bath, then stirred at 100 rpm. Then, 3 mL of solution was withdrawn at appropriate intervals (0.5, 1, 2, 3, 4, 5, 6, 8, 12 and 24 h). The filtrate (VCM) was replaced by 3 mL of fresh buffer. The amount of VCM in the release medium was determined by UV at 279.8 nm (12, 13).

In order to have a better comparison between different formulations dissolution efficiency (DE), \( t_{50\%} \) (dissolution time for 50% fraction of drug) and difference factor, \( f_i \) (used to compare multipoint dissolution profiles) were calculated and the results are listed in Table 2. DE is defined as the area under the dissolution curve up to a certain time (\( t \)), expressed as a percentage of the area of the rectangle arising from 100% dissolution in the same time. The areas under the curve (AUC) were calculated for each dissolution profile by the trapezoidal rule (14). DE can be calculated by the following:

\[
\text{DE} = \frac{\int_0^t y \, dt}{100} \times 100%
\]

Here, \( y \) is the drug percentage dissolved at time \( t \). All dissolution efficiencies were obtained with \( t \) equal to 1440 min. The *in-vitro* release profiles of different nanoparticle formulations were compared with physical mixture formulation using difference factor (\( f_i \)), as defined by:

\[
f_i = \frac{\left(\sum_{t=1}^{n} |R_t - T_t|\right)}{\left(\sum_{t=1}^{n} R_t\right)} \times 100
\]

Here, \( n \) is the number of time points at which %dissolved was determined. \( R \) is the %dissolved of one formulation at a given time point and \( T \) is the %dissolved of the formulation to be compared at the same time point. The difference factor fits the result between 0 and 15, when the test and reference profiles are identical and approaches above 15 as the dissimilarity increases.

Data obtained from *in-vitro* release studies were fitted to various kinetic equations to find out the mechanism of drug release from the Eudragit RS100 nanoparticles. The kinetic models used were:

\[
Q_t = k_0 t \quad \text{(zero-order equation)}
\]

\[
\ln Q_t = \ln Q_0 - k_1 t \quad \text{(first-order equation)}
\]

\[
Q_t = K \times S \times t^{0.5} \quad \text{(Higuchi equation based on Fickian diffusion)}
\]

Here, \( Q \) is the amount of drug release in time \( t \), \( Q_0 \) is the initial amount of drug in the nanoparticles, \( S \) is the surface area of the nanoparticle and \( k_0, k_1 \) and \( k_{H} \) are rate constants of zero order, first order and Higuchi equation, respectively. In addition to these basic release models, the release data was fitted to the Peppas and Korsmeyer equation (power law):

\[
\frac{M_t}{M_\infty} = k_t^n
\]

Here, \( M_t \) is the amount of drug release at time \( t \).
\( t \) and \( M_t \) is the amount released at time \( t = \infty \), thus \( M_t / M_\infty \) is the fraction of drug released at time \( t \), \( k \) is the kinetic constant, and \( n \) is the diffusion exponent which can be used to characterize the mechanism of drug release (14, 15).

**Optimization of the VCM nanoparticles**

Response surface methodology (RSM) is a very useful statistical technique for the optimization of VCM formulations. In this design, 5 factors were evaluated, each at 4 levels, and experimental trials were performed at all 27 possible combinations. The amounts of emulsifier (\( X_1 \)), volume of organic solvent (\( X_2 \)) and the amount of dispersing medium (\( X_3 \)), were selected as independent variables. The drug content (DC), loading efficiency (LE), particle size (PS), and percentage production yield (PY) were dependent variables (Table 3).

Various batches of the selected formulation (F_2) were made, but the stirring rate was the only parameter that was varied between 22000, 24000 and 26000 rpm. In addition, while keeping the other parameter constant, time of homogenizer stirring was changed (1.5, 3 and 4.5 min). After drying, the weighed batch of nanoparticles was subjected to drug content, loading efficiency, particle size and drug release experiments.

The influence of process variables on nanoparticle formation, micromeritics and drug release characteristics, was investigated. These variables included the emulsifier concentration (0.1, 0.2 and 0.4%) and volume of organic solvent (15, 20 and 25 mL) and dispersing medium (15, 25 and 35 mL).

**Regression analysis**

The targeted response parameters were statistically analyzed by applying one-way ANOVA at 0.05 levels. Individual response parameters were evaluated using the F-test and quadratic models of the form given below were generated for each response parameter using the multiple linear regression analysis (17).

\[
Y = b_0 + b_1 X_1 + b_2 X_2 + b_3 X_3 + b_4 X_4 + b_5 X_5 + b_{11} X_1^2 + b_{12} X_1 X_2 + b_{13} X_1 X_3 + b_{14} X_1 X_4 + b_{15} X_1 X_5 + b_{23} X_2 X_3 + b_{24} X_2 X_4 + b_{34} X_3 X_4 + b_{35} X_3 X_5 + b_{45} X_4 X_5
\]

In this equation, \( Y \) is the predicted response, \( X_1, X_2, X_3, X_4 \) and \( X_5 \) are independent variables, \( b_0 \) is the intercept, \( b_1, b_2, b_3, b_4 \) and \( b_5 \) are linear effects, \( b_{11}, b_{12}, b_{13}, b_{14}, b_{15}, b_{23}, b_{24}, b_{34} \) and \( b_{45} \) are interaction terms. The main effects (\( X_1, X_2, X_3, X_4 \) and \( X_5 \)) represent the average result of changing one factor at a time from its low to high value. The interaction terms (\( X_1 X_2, X_1 X_3, X_1 X_4, \) and \( X_1 X_5 \)) show how the response changes when five factors are simultaneously changed. The polynomial terms (\( X_1 X_1, X_2 X_2, X_3 X_3, X_4 X_4 \) and \( X_5 X_5 \)) are included to investigate nonlinearity. Three-dimensional surface (3D) plots were drawn to illustrate the main and interactive effects of the independent variables on production yield, drug content, loading efficiency and particle size. The optimum values of the selected variables were obtained from the software and also from the response surface plots.

Numerical optimization using the desirability approach was employed to locate the optimal settings of the formulation variables to obtain the desired response (17). An optimized formulation was developed by setting the constraints on the dependent and independent variables. The formulation developed was evaluated for the responses and the experimental values obtained were compared with those predicted by the mathematical models generated.

**Results and Discussion**

A W/O/W multiple emulsion solvent evaporation/extraction method is mostly used for the encapsulation of water-soluble drug and therefore was the method of choice for the water-soluble VCM drug. Droplets of the polymer in organic solution were added to a solution PVA (as stabilizer) aqueous solution. At the end, the uniform-sized beads were collected (18). In the nanoparticles prepared by the evaporation method, the amount of drug entrapped in microspheres was lower than the theoretical value. This indicates that some free drug crystals were lost in the process of encapsulation. By the increase of drug to polymer ratio, the amount of free drug lost is decreased (Table 1) so that at
the ratio of 1:3 in drug to polymer, the amount of drug entrapment was 23.69% which was very close to the theoretical value (25%).

The encapsulation efficiency of the drug depends on the solubility of the drug in the solvent and continuous phase (19). Important prerequisites for high encapsulation efficiencies by the W/O/W method are: (1) the insolubility of the drug in the external phase, and (2) the fine dispersion of the aqueous drug solution into the organic polymer solution to form a W/O emulsion (20). VCM is insoluble in methylene chloride used to dissolve the polymer and thus cannot part from the internal into the external phase. Entrapment efficiency of polypeptides is increased by enhancing the viscosity builders (21). Despite the hydrosolubility of VCM, favoring the leakage of the drug into the external aqueous phase, the entrapment efficiencies were rather high (22). It is assumed that VCM is localized at the interfaces (either internal water in oil or external oil in water). Therefore, a significant amount of drug is supposed to be adsorbed at the outer surface. In addition, the

Table 3. Response surface regression Evaluation of VCM formulations in full factorial design.

<table>
<thead>
<tr>
<th>Formulation code</th>
<th>Variable levels in coded form</th>
<th>PS (nm)</th>
<th>LE (%)</th>
<th>DE (%)</th>
<th>PY (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>26000 15 20 1.5 0.1</td>
<td>480</td>
<td>80</td>
<td>26</td>
<td>94</td>
</tr>
<tr>
<td>F2</td>
<td>26000 15 25 3 0.2</td>
<td>502</td>
<td>82</td>
<td>29</td>
<td>95</td>
</tr>
<tr>
<td>F3</td>
<td>26000 15 30 4.5 0.4</td>
<td>570</td>
<td>81</td>
<td>28.5</td>
<td>96</td>
</tr>
<tr>
<td>F4</td>
<td>26000 20 20 1.5 0.1</td>
<td>490</td>
<td>82</td>
<td>29</td>
<td>97</td>
</tr>
<tr>
<td>F5</td>
<td>26000 20 25 3 0.2</td>
<td>468</td>
<td>79</td>
<td>31.2</td>
<td>98.6</td>
</tr>
<tr>
<td>F6</td>
<td>26000 20 30 4.5 0.4</td>
<td>510</td>
<td>85</td>
<td>30.2</td>
<td>98.2</td>
</tr>
<tr>
<td>F7</td>
<td>26000 25 20 1.5 0.1</td>
<td>580</td>
<td>84</td>
<td>30.8</td>
<td>96.5</td>
</tr>
<tr>
<td>F8</td>
<td>26000 25 25 3 0.2</td>
<td>520</td>
<td>88</td>
<td>31.5</td>
<td>98.1</td>
</tr>
<tr>
<td>F9</td>
<td>26000 25 30 4.5 0.4</td>
<td>590</td>
<td>88</td>
<td>30.7</td>
<td>98.2</td>
</tr>
<tr>
<td>F10</td>
<td>24000 15 20 1.5 0.1</td>
<td>490</td>
<td>83</td>
<td>26.3</td>
<td>94</td>
</tr>
<tr>
<td>F11</td>
<td>24000 15 25 3 0.2</td>
<td>476</td>
<td>81</td>
<td>27</td>
<td>95.2</td>
</tr>
<tr>
<td>F12</td>
<td>24000 15 30 4.5 0.4</td>
<td>520</td>
<td>86</td>
<td>28.1</td>
<td>95.7</td>
</tr>
<tr>
<td>F13</td>
<td>24000 20 20 1.5 0.1</td>
<td>480</td>
<td>77</td>
<td>25.7</td>
<td>94.5</td>
</tr>
<tr>
<td>F14</td>
<td>24000 20 25 3 0.2</td>
<td>442</td>
<td>87</td>
<td>28.8</td>
<td>97.7</td>
</tr>
<tr>
<td>F15</td>
<td>24000 20 30 4.5 0.4</td>
<td>526</td>
<td>90</td>
<td>30.1</td>
<td>98.1</td>
</tr>
<tr>
<td>F16</td>
<td>24000 25 20 1.5 0.1</td>
<td>490</td>
<td>88</td>
<td>29</td>
<td>96.8</td>
</tr>
<tr>
<td>F17</td>
<td>24000 25 25 3 0.2</td>
<td>575</td>
<td>90</td>
<td>30.1</td>
<td>97.9</td>
</tr>
<tr>
<td>F18</td>
<td>24000 25 30 4.5 0.4</td>
<td>520</td>
<td>90.1</td>
<td>30.3</td>
<td>97.8</td>
</tr>
<tr>
<td>F19</td>
<td>22000 15 20 1.5 0.1</td>
<td>450</td>
<td>87.1</td>
<td>25.2</td>
<td>93.4</td>
</tr>
<tr>
<td>F20</td>
<td>22000 15 25 3 0.2</td>
<td>440</td>
<td>88</td>
<td>26.5</td>
<td>64.5</td>
</tr>
<tr>
<td>F21</td>
<td>22000 15 30 4.5 0.4</td>
<td>473</td>
<td>89</td>
<td>25.8</td>
<td>94.7</td>
</tr>
<tr>
<td>F22</td>
<td>22000 20 20 1.5 0.1</td>
<td>410</td>
<td>89</td>
<td>26.3</td>
<td>94.1</td>
</tr>
<tr>
<td>F23</td>
<td>22000 20 25 3 0.2</td>
<td>415</td>
<td>93</td>
<td>26.3</td>
<td>96.6</td>
</tr>
<tr>
<td>F24</td>
<td>22000 20 30 4.5 0.4</td>
<td>435</td>
<td>91.5</td>
<td>28.2</td>
<td>94.3</td>
</tr>
<tr>
<td>F25</td>
<td>22000 25 20 1.5 0.1</td>
<td>465</td>
<td>91.5</td>
<td>27.8</td>
<td>94.1</td>
</tr>
<tr>
<td>F26</td>
<td>22000 25 25 3 0.2</td>
<td>472</td>
<td>92.8</td>
<td>29.1</td>
<td>95.3</td>
</tr>
<tr>
<td>F27</td>
<td>22000 25 30 4.5 0.4</td>
<td>495</td>
<td>93.1</td>
<td>29.3</td>
<td>95.9</td>
</tr>
</tbody>
</table>

All formulations contained 100 mg VCM, 5 mL water, 200 mg Eudragit RS, 20 mL dichloromethane and 25 mL 0.2% PVA. †X1 is RPM and; X2 is volume of organic solvent.; X3 is dispersing medium; X4 is time of stirring; X5 is concentration of emulsifier; DE indicates drug entrapped; LE, loading efficiency; PS= particle size; PY, production yield.
removal of the organic solvent under reduced pressure favors its fast evaporation followed by the polymer precipitation and thus, reduces the migration of the drug to the external phase. Indeed, the faster the solvent evaporation, the higher the encapsulation efficiency (22). One possible explanation could concern the increase of the primary emulsion viscosity due to the different VCM concentrations studied which could reduce the leakage of the drug towards the external aqueous phase (23). Generally, increasing the polymer to drug ratio increased the production yield, when the ratio of polymer:drug increased from 1:1 to 1:3, the production yield was increased (p > 0.05). Size of microspheres was found to be increased with the increase in the concentration of polymer (Table 1). It can be attributed to the fact that with the higher diffusion rate of non-solvent to polymer solution, the smaller size of microcapsules is easily obtained (22, 23). A volume-based size distribution of drug, polymer, and drug-loaded nanoparticles indicated a log-probability distribution. Mean particle size of F_3 was 499 ± 110 nm. The data describing the particle sizes of the nanoparticles are given in Table 1. As it can be seen, the particle size is increased with increasing the polymer amount. It has already been reported that particle size is proportional to the viscosity of dispersed phase (10, 23-25). In fact, viscosity of dispersed phase was increased from F_1 (1:1) to F_3 (1:3). When the viscosity of the dispersed phase of these formulations was investigated, it was found that particle sizes of nanoparticles were directly proportional to the apparent viscosity of dispersed phase. The results showed that the apparent viscosities of the different drugs polymer ratios (1:1, 1:2 and 1:3) were 13, 16 and 18.8 mPa.s respectively. When the dispersed phase with higher viscosity was poured into the dispersion medium, bigger droplets were formed with larger mean particle size.

The zeta potential of three nanosphere formulations, VCM and Eudragit RS100 are shown in Table 1. Blank nanoparticles had positive charge (15.7 mV). Drug-loaded nanoparticle indicated more positive charge, which could be ascribed to the cationic nature of VCM. Zeta potential is the potential difference, the dispersion medium and the stationary layer of fluid attached to the dispersed particle. A value of potential zeta (positive) can be taken as the arbitrary value that separates low-charged surfaces from highly-charged surfaces. The significance of zeta potential is that its value can be related to the stability of colloidal dispersion. The zeta potential indicates the degree of repulsion between adjacent, similarly charged particles in dispersion. For molecules and particles that are small enough, a high zeta potential will confer the stability, i.e. the solution or dispersion will resist aggregation (23, 27).

The in-vitro release profiles of VCM from nanoparticles (Table 2) exhibited initial burst effect, which may be due to the presence of some drug particles on the surface of the nanoparticles. In most cases, a biphasic dissolution profile was observed at pH of 7.4 as follows: the initial rapid drug leakage generally ended very early and for the remaining time, nearly linear behavior was observed. The first portion of the dissolution curves is due to VCM dissolution, which starts immediately after the beginning of the test for the portion of drug on the surface of nanoparticles. After such a phase, two phenomena can be combined in enhancing in the diffusion of the remaining dispersed drug into the bulk phase as well as the formation of pores within the matrix due to the initial drug dissolution; particle wetting and swelling which enhances the permeability of the polymer to the drug (Table 2). The results indicated that some factors such as drug-polymer ratio governed the drug release from these nanoparticles. Drug release rates were decreased with increasing the amounts of polymer in the formulation (Table 2). Higher level of VCM corresponding to lower level of the polymer in the formulation resulted in an increase in the drug release rate (F_1). As more drugs are released from the nanoparticles, more channels are probably produced, contributing to faster drug release rates. However, Table 2 shows that the burst effect is lower when the drug to polymer ratio is 1:3 (F_3) compared with other formulations. In the formulation F_3, a decreased diffusivity due to the high polymer concentration could reduce the leakage of the drug towards the dissolution medium and decrease the burst effect (to compare with F_1 and F_2).
VCM nanoparticles of each formulation displayed an immediate and important initial drug release in the first 2 h (22-40%), followed by an 84-87% during 24 h (Table 2). An immediate high release may be due to the small diameter of nanoparticles leading to a large exchange surface and probably to a more porous structure owing to the solvent evaporation method, favoring the release of the encapsulated drug (28). Indeed, it has been already demonstrated that the slow precipitation of nanoparticles after the solvent evaporation leads to more porous particles compared to the fast polymer precipitation obtained after the solvent extraction (23). The presence of Eudragit RS100 in the matrix of nanoparticles conferred a slower and more progressive release of VCM during the time of the experiment (11). Therefore, any mechanism which is able to restrict the diffusion of VCM towards water would be easily observed, due to the slow diffusion of water into the lipophilic Eudragit RS100 matrix (7, 11, 23-25). F1, F2 and F3 nanoparticles showed lower dissolution efficiency, i.e. slower dissolution in comparison with respective physical mixture (p < 0.05), (Table 2). According to Table 2, the lowest DE was observed for F1 (66.37%) and the dissolution efficiency of the physical mixture was 98.03% (p < 0.05). The value of t50% varied between 2.24 (F2 formulation) and 4.85 h (F3 formulation). The results of similarity factor (f2) showed that the release profile of nanoparticle formulations is different from that of physical mixture (Table 2).

The independent variables and their levels were selected based on the preliminary trials undertaken. The %DT, %LE, PS and %PY for the formulations (F1 to F27) showed a wide variation. The data clearly indicated that the %DT, %LE, PS and %PY values are strongly dependent on the selected independent variables. The fitted equations (full and reduced) that relates the responses PY and %F to the transformed factors are shown in Table 4. The polynomial equations can be used to draw conclusions after considering the magnitude of coefficient and the mathematical sign it carries (i.e., positive or negative). Table 4 shows the results of the analysis of variance (ANOVA), which was performed to identify the insignificant factors. The high values of correlation coefficient for %DC, %LE, %PY and PS indicate a good fit i.e., good agreement between the dependent and independent variables. The equations may be used to obtain estimates of the response as a small error of variance was noticed in the replicates. The significance test regression coefficient was performed by applying the Student F-test.

The results of statistical analysis are shown in Table 5. Calculations for testing the model in portions.

### Table 4. Equations Response surface regression.

<table>
<thead>
<tr>
<th>Response coefficients</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>PY = 628.18 + 0.01 X1 - 1.70 X2 - 64.27 X3 + 85.17 X4 + 2134.91 X5 - 0.08 X22 - 14.14 X44 - 0.04 X1X5 + 0.70 X2X3 - 23.49 X2X5</td>
<td>PY versus X1, X2, X3, X4, X5</td>
</tr>
<tr>
<td>DE= 145.828 - 0.003 X1 - 0.374 X2 - 9.814 X3 + 30.317 X4 + 276.106 X5 + 0.005 X22 - 4.268 X44 - 0.004 X1X5 + 0.006 X2X3 - 0.349 X2X5</td>
<td>DE versus X1, X2, X3, X4, X5</td>
</tr>
<tr>
<td>LE = 231.175 - 0.014 X1 - 3.443 X2 + 4.318 X3 + 3.412 X4 + 65.562 X5 + 0.041 X22 - 4.469 X44 + 0.009 X1X5 + 0.128 X2X3 - 4.59 X2X5</td>
<td>LE versus X1, X2, X3, X4, X5</td>
</tr>
<tr>
<td>PS = -295.585 + 0.264 X1 - 103.5 X2 - 86.137 X3 + 620.407 X4 - 197.217 X5 + 1.746 X22 - 47.18 X44 - 0.005 X1X3 + 0.163 X1X5 + 1.685 X2X3 - 56.882 X2X5</td>
<td>PS versus X1, X2, X3, X4, X5</td>
</tr>
</tbody>
</table>

### Table 5. Calculations for testing the model in portions.

<table>
<thead>
<tr>
<th>Response coefficients</th>
<th>DF</th>
<th>SS</th>
<th>MS</th>
<th>F([alpha])</th>
<th>R2</th>
<th>p</th>
<th>MPE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PY</td>
<td>13</td>
<td>639.58</td>
<td>49.20</td>
<td>1.65</td>
<td>62.24</td>
<td>0.190</td>
<td>6.54</td>
</tr>
<tr>
<td>DE</td>
<td>13</td>
<td>84.48</td>
<td>6.50</td>
<td>9.89</td>
<td>90.82</td>
<td>0.000</td>
<td>2.14</td>
</tr>
<tr>
<td>LE</td>
<td>13</td>
<td>456.246</td>
<td>35.10</td>
<td>5.09</td>
<td>83.59</td>
<td>0.003</td>
<td>2.60</td>
</tr>
<tr>
<td>PS</td>
<td>13</td>
<td>52135.5</td>
<td>4010.42</td>
<td>6.84</td>
<td>87.25</td>
<td>0.001</td>
<td>2.77</td>
</tr>
</tbody>
</table>
in Table 5. The coefficients $b_1$, $b_2$, and $b_{11}$ were found to be significant at $p < 0.05$; hence they were retained in the reduced model.

The reduced model was tested in portions to determine whether the coefficients $b_{12}$ and $b_{22}$ contribute significant information for the prediction of PY or not. The results for testing the model in portions are depicted in Table 5. Hence, conclusions can be drawn considering the magnitude of the coefficient and the mathematical sign (positive or negative) it carries. According to Figure 1, particle size is dependent on major independent factors such as rpm and volume of organic phase.
The results show that linear and interaction components in the proposed model are not very significant ($R^2 = 87.25$).

The optimum condition for VCM nanoparticles preparation was 1:2 (v/w) drug to polymer ratio, 0.2 (%w/w) amount of emulsifier, 25 mL (volume of organic phase), 25 mL (volume of aqueous phase), 3 min (time of stirring) and 26000 rpm. Emulsifier concentrations and rpm were the most effective factors on the drug loading ($R^2 = 90.82$) (Table 5 and Figure 2). The results obtained from the predicted model were used to create a contour plot for loading efficiency and the production yield is shown in Figure 3. Emulsifier concentration and rpm affect on the loading efficiency and production yield ($R^2 = 83.59$).

An increase in the concentration of VCM leads to an increase in drug loading and loading efficiency since the coefficient $b_2$ bears a positive sign. An increase in the time of stirring leads rpm and concentration of emulsifier to an increase in the mean particle size as the coefficient $b_2$ bears a positive sign. The increase in rpm results in decreased PS values (Table 5).

The in-vitro release profiles were fitted on various kinetic models in order to find out the mechanism of drug release (29, 30). The rate constants were calculated from the slope of the respective plots. High correlation was observed for the Peppas model. The data obtained were also put in Korsmeyer-Peppas model in order to find out n-value, which describes the drug release mechanism. The n-value of microspheres of different drug to polymer ratio was in the range of 0.51-0.91 (Table 6), indicating that the mechanism of the drug release was diffusion and erosion controlled.

**Conclusion**

VCM nanoparticles were prepared using double emulsion (W/O/W) solvent evaporation method. Drug polymer ratio, stirring speed, time of stirring, emulsifier, dispersing medium and organic solvent influenced the characteristics of the nanoparticles. The entrapment efficiency was high for all formulations. It was observed that at higher drug concentration, the mean particle size of the nanoparticles is high but increasing the stirring speed and emulsifier content, resulted in smaller mean particle size of nanoparticles. High correlation was observed for the Peppas model. The data obtained were also put in Korsmeyer-Peppas model in order to find out n-value, which describes the drug release mechanism. The n-value
Statistical Optimization of Oral Vancomycin-Eudragit RS

of nanoparticles of different drug to polymer ratio was in the range of $0 < n < 0.5$, indicating that the mechanism of the drug release was diffusion controlled. It was suggested that the mechanism of drug release from nanoparticles was diffusion-controlled. A response surface methodology has been employed to produce VCM nanoparticles for oral delivery in Eudragit RS by double emulsion. The formulation variables studied exerted a significant influence on PY, DC, LE and PS. The obtained results indicate that the response surface methodology can be employed successfully to qualify the effect of several formulation and processing variables and thereby, minimize the number of experimental trials and reduce the formulation development cost.

Acknowledgment

The financial support from biotechnology center, Tabriz University of Medical Sciences, is greatly acknowledged.

References

(12) Jelvehgari M, Barar J, Valizadeh H and Heidari N.


This article is available online at http://www.ijpr.ir